TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Pioglitazone on Macrovascular Outcome in Patients With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~* Type 2 diabetes mellitus~* Glycosylated hemoglobin above the upper limit of normal (ie, the local equivalent of 6.5% for)~* Established history of macrovascular disease, defined as 1 or more of:~  * Myocardial infarction at least 6 months before entry into the study.~ * Stroke at least 6 months before entry into the study~ * Percutaneous coronary intervention or coronary artery bypass graft at least 6 months before entry into the study.~ * Acute coronary syndrome at least 3 months before entry into the study.~ * Objective evidence of coronary artery disease.~ * Peripheral arterial obstructive disease~Exclusion Criteria~* Signs of type 1 diabetes.~* Patients prescribed insulin as sole therapy for glycemic control of diabetes for 2 weeks or more at any time in the previous 3 months.~* Myocardial infarction, stroke, coronary artery bypass graft, or percutaneous cardiac intervention in the 6 months prior to enrolment.~* Acute coronary syndrome in the 3 months prior to enrolment.~* Heart failure at entry defined as patient having a New York Heart Association functional score of II or above.~* Had an appointment for a coronary angiogram or endovascular or surgical intervention.~* Leg ulcers, gangrene, or ischemic rest pain.~* Had an appointment for an angiogram or endovascular or surgical intervention for leg ischemia.~* Had undergone a major operation (defined as a surgical procedure lasting for more than 30 minutes) at any time in the previous 4 weeks.~* Significantly impaired hepatic function, defined as alanine aminotransferase greater than 2.5 times the upper limit of normal.~* Familial polyposis coli.~* Required dialysis.~* History of alcohol or drug abuse.~* Any other intercurrent disease believed to be likely to have a significant impact on the patient's life expectancy during the course of the study (eg, cancer).~* Patient was undergoing follow-up as part of another clinical trial or less than 3 months had elapsed since the last dose of an investigational drug or procedure.~* Hypersensitivity to pioglitazone or other TZD.~* Current use of pioglitazone or other TZD.~* Patient was known to be infected with human immunodeficiency virus or was known to have viral hepatitis.~* Women who were any of the following: pregnant, breast feeding, wished to become pregnant during the course of the study or of childbearing potential and not planning to use a reliable method of contraception throughout the study.

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Pioglitazone QD (Type: EXPERIMENTAL): None
- Placebo QD (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: ADVATE/ ADYNOVI Hemophilia A Outcome Database (AHEAD)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Participant has hemophilia A {FVIII lesser than or equal to (\<=)5%}~* Participant is prescribed Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method (rAHF-PFM) or Antihemophilic Factor (Recombinant) - Pegylated (rAHF-PEG) by the treating physician~* Participant or participant's legally authorized representative provides informed consent~Exclusion Criteria:~* Participant has known hypersensitivity to the active substance or any of the excipients~* Participant has known allergic reaction to mouse or hamster proteins~* Participant has participated in another clinical study involving an investigational product (IP) or device within 30 days prior to study enrollment or is scheduled to participate in another clinical study involving another FVIII concentrate or device during the course of this study

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- rAHF-PFM (Type: None): Participants treated with rAHF-PFM alone
- rAHF-PEG (Type: None): Participants treated with rAHF-PEG alone
- rAHF-PFM then rAHF-PEG (Type: None): Participants treated with rAHF-PFM and subsequently switched to rAHF-PEG

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Short Versus Extended Antibiotic Treatment With a Carbapenem for High-risk Febrile Neutropenia in Hematology Patients With FUO

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with malignant hematological diseases being treated with cytotoxic chemotherapy or stem cell transplantation;~2. High-risk neutropenia (Absolute neutrophil count (ANC) \<0.5x109/L which is expected to last longer than 7 days);~3. Fever (One single measured tympanic membrane temperature of \>38.5°C or a temperature of \>38.0°C during 2 subsequent measurements separated by at least 2 hours);~4. Age 18 years or older;~5. Written informed consent.~Exclusion Criteria:~1. Contraindications to use of imipenem-cilastatin or meropenem such as allergy, previous severe side-effects or previous microbiological cultures with carbapenem-resistant microorganism(s).~2. Corticosteroid use ≥10 mg per day prednisolone or equivalent for more than 3 consecutive day during the previous 7 days.~3. Clinically or microbiologically documented infection.~4. Symptoms of septic shock (systolic blood pressure \<90 mm Hg unresponsive to fluid resuscitation and/or oliguria (urine production \<500mL/day).~5. Previous enrollment in this study during the same episode of neutropenia.~6. Any critical illness for which Intensive Care Unit treatment is required.~7. Legal incompetency

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Short treatment (Type: EXPERIMENTAL): Discontinuation of imipenem-cilastatin or meropenem after 3x24 hours irrespective of presence of fever.
- Extended treatment (Type: NO_INTERVENTION): Extended treatment with imipenem-cilastatin or meropenem for at least 6 more days. The treatment with a carbapenem will be continued until patients have been treated for at least 9x24 hours and have been afebrile (tympanic membrane temperature \<38.0°C) for at least five consecutive days or until resolution of neutropenia (ANC \> 0,5 x10\^9/L), whichever comes first.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Changes in Health and Functional Status in Patients With Chronic Obstructive Pulmonary Disease During Therapy With Spiolto® Respimat® (AERIAL®)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Patients can be included if all of the following criteria are met:~* Written informed consent prior to participation~* Female and male patients ≥40 years of age~* Patients diagnosed with COPD and requiring a combination of two long-acting bronchodilators (LAMA + LABA) according to approved SmPC and GOLD COPD guideline recommendation 2017 (GOLD COPD groups B to D)~* Treatment with Spiolto® Respimat® acc. to SmPC at the discretion of the physician.~Exclusion Criteria:~* Patients with contraindications according to Spiolto® Respimat® SmPC~* Patients already on a LABA/LAMA combination (free and fixed dose) in the last 6 weeks before study entry~* Patients continuing LABA-ICS treatment should not be additionally treated with Spiolto® Respimat® in order to avoid a double dosing of long-acting beta-agonists~* Pregnancy and lactation~* Current participation in any clinical trial or any other non-interventional study of a drug or device.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- patients treated with Spiolto® Respimat® (Type: None): Patients with COPD

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study in Myeloproliferative Disorders

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Have a diagnosis of polycythemia vera (PV), essential thrombocythemia (ET), or myelofibrosis (MF) as defined by the World Health Organization (WHO) diagnostic criteria for myeloproliferative neoplasms and meet the following additional sub-type specific criteria:~A. PV: has failed or is intolerant of standard therapies or refuses to take standard medications~B. ET: has failed or is intolerant of standard therapies or refuses to take standard medications~C. MF (patients with MF must meet at least one of the following):~i. has intermediate or high-risk MF according to the Lille scoring system; or~ii. has symptomatic MF with spleen greater than 10 cm below left costal margin; or~iii. has post-polycythemic MF; or~iv. has post-ET MF~* Have a quantifiable JAK2 V617F mutation~* Have discontinued all previous approved therapies for myeloproliferative disorders, including any chemotherapy, immunomodulating therapy (for example, thalidomide, interferon-alpha), immunosuppressive therapy (for example, corticosteroids greater than 10 mg/day prednisone or equivalent), radiotherapy, and erythropoietin, thrombopoietin, or granulocyte colony stimulating factor for at least 14 days and recovered from the acute effects of therapy. Hydroxyurea used to control blood cell counts is permitted at study entry if the subject has been maintained on a stable dose for at least 4 weeks. Low-dose acetylsalicylic acid (aspirin) is permitted as well~Exclusion Criteria:~* Have received treatment within 14 days of the initial dose of study drug with an experimental agent that has not received regulatory approval for any indication~* Are currently being treated with agents that are metabolized by CYP3A4 with a narrow therapeutic margin (for example, alfentanil, cyclosporine, diergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus) or CYP2B6 (for example, cyclophosphamide, ifosfamide, tamoxifen, efavirenz, propofol, methadone, and bupropion)~* Are currently being treated with warfarin or one of its derivatives which is known to alter levels of protein C or protein S. An exception to this criterion will be allowed for patients with a prior history of Budd-Chiari Syndrome who are being treated with warfarin or one of its derivatives

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LY2784544 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Hypertension With Adalat® in Combination With Other Drugs

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Previously untreated hypertensive patients starting with combination therapy containing nifedipine or~* Insufficiently controlled hypertensive pts. receiving nifedipine as an add-on to existing non-CCB (calcium-channel-blocker) containing antihypertensive therapy~Exclusion Criteria:~* None. Exclusion criteria are defined by contraindications and precautions as stated in the local product information.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of MHAA4549A in Healthy Volunteers in an Influenza Challenge Model

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* In good health with no history of major medical conditions from medical history, physical examination and routine laboratory tests~* Male subjects and women of child-bearing potential must use effective contraception as defined by protocol, starting at entry to quarantine and continuing until Day 120 follow-up visit~* Sero-suitable for challenge virus~Exclusion Criteria:~* Women who have been pregnant within 6 months prior to the study, or who have been breastfeeding within 3 months prior to the study, or who have a positive pregnancy test at any point in the study~* Any history or evidence of any clinically significant cardiovascular, gastrointestinal, endocrinological, haematological, hepatic, immunological, metabolic, urological, neurological, psychiatric, renal, and/or other major disease or malignancy, as judged by the CI~* Abnormal pulmonary function evidenced by clinically significant abnormalities in spirometry~* History of asthma, COPD, pulmonary hypertension, reactive airway disease, or chronic lung disease of any etiology. A history of childhood asthma before the age of 12 is acceptable provided the subject is asymptomatic without treatment.~* History suggestive of respiratory infection within 14 days prior to admission to the unit

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- MHAA4549A (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None
- Tamiflu (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Expanded PrEP Implementation in Communities in NSW

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* HIV negative at enrolment, with a negative HIV test result documented within seven days of initiating PrEP~* At high and ongoing risk for acquiring HIV infection through sexual exposure (as defined by Behavioural Eligibility criteria presented in Appendix II and online Risk Assessment Questionnaire in Appendix III), OR previously a PrELUDE study participant~* Aged 18 years or over~* Live in NSW or ACT or visit NSW or ACT enough to attend clinics for follow-up assessments~* Willing and able to provide informed consent~* Medicare ineligible individuals may be enrolled if the clinical service is able to cover the costs of monitoring of the patient~Exclusion Criteria:~* HIV-1 infected or has symptoms consistent with acute viral infection (If HIV positive status is not confirmed by testing, delay starting PrEP for at least one month and reconfirm negative HIV-1 status).~* Having an estimated creatinine clearance (glomerular filtration rate \[GFR\]) \<60ml/min~* Having or developing clinical symptoms suggestive of lactic acidosis or pronounced hepatotoxicity (including nausea, vomiting, unusual or unexpected stomach discomfort, and weakness)~* Concurrently taking a nephrotoxic agent (e.g., high-dose non-steroidal anti-inflammatory drugs / NSAIDs)~* Allergic to TDF and/or FTC (based on self-report or recorded)~* Concurrently taking prescribed products containing FTC or TDF including ATRIPLA®, COMPLERA®, EMTRIVA, STRIBILD®, VIREAD, TAF (tenofovir alafenamide), GENVOYA, DESCOVY; other drugs containing lamivudine; HEPSERA~* Factors or conditions that may compromise a participant's access to health services for follow-up (incarceration or planned relocation and potential absence from NSW or ACT).~Behavioural eligibility criteria as per NSW PrEP guidelines.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- treatment (Type: EXPERIMENTAL): A single open-label arm. All participants receive daily oral pill containing TDF/FTC

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Yoga, Immune Function, and Health

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* healthy female adults~* relatively inexperienced with yoga (beginner)~* experienced with yoga (advanced practitioner)~Exclusion Criteria:~* Treatment with medication that has immunological or endocrinological consequences~* Chronic health problems that affect immune or endocrine systems~* Anemia~* Use of psychoactive drugs or mood-altering medication~* Smoking~* Needle or blood phobias~* Tape or bandage allergies~* Pregnancy or nursing within the previous 3 months~* Heart problems~* History of hip or knee replacement surgery, displaced vertebrae, and any other physical limitations that would prevent full participation in the program~* use of statins, beta blockers~* excessive alcohol use~* convulsive disorders~* Body Mass Index (BMI) ≥ 30.

- Gender: FEMALE
- Minimum Age: 30 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Hatha yoga classes (Type: EXPERIMENTAL): Groups consisted of novices or experts. Groups were counterbalanced to ensure that equal number of novices and experts participated in each possible session combination, in a randomly assigned order.
- Movement Control (Type: SHAM_COMPARATOR): Non-Hatha yoga gentle movement. Groups consisted of novices or experts. Groups were counterbalanced to ensure that equal number of novices and experts participated in each possible session combination, in a randomly assigned order.
- Passive Video Control (Type: NO_INTERVENTION): Another control condition, a neutral video that did not include any music, allowed us to contrast the effects of yoga with no activity.The session included a sequence on how to design physics experiments for a high school classroom, as well as segments from two lectures on polymers and quantum mechanics. Groups were counterbalanced to ensure that equal number of novices and experts participated in each possible session combination, in a randomly assigned order.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Cariprazine in Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who have provided informed consent prior to any study specific procedures~* Patients currently meeting the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) criteria for schizophrenia (paranoid type, disorganized type, catatonic type or undifferentiated type), as confirmed by the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (SCID)~* Structured Clinical Interview for the Positive and Negative Syndrome Scale (SCIPANSS) total score ≥ 80 and ≤ 120~* Diagnosis of schizophrenia for a minimum of 1 year before Visit 1~* Patients with normal physical examination, laboratory, vital signs,and/ or electrocardiogram (ECG)~Exclusion Criteria:~* Patients with a DSM-IV-TR diagnosis of Schizoaffective disorder, schizophreniform disorder, other psychotic disorders other than schizophrenia, or bipolar I or II disorder~* Patients in their first episode of psychosis~* Pregnant, breast-feeding, and/or planning to become pregnant and/or breastfeed during the study~* Pervasive developmental disorder, mental retardation, delirium, dementia, amnestic and other cognitive disorders~* Known or suspected borderline or antisocial personality disorder or other DSM-IV-TR axis II disorder of sufficient severity to interfere with participation in this study~* Substance abuse or dependence within the prior 3 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Cariprazine (3-6 mg/day) (Type: EXPERIMENTAL): Cariprazine once daily fixed-flexible low dose
- Cariprazine (6-9 mg/day) (Type: EXPERIMENTAL): Cariprazine once daily fixed-flexible high dose
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Impact of Udenafil on Exercise Capacity in Severe Chronic Obstructive Pulmonary Disease (COPD) Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Severe COPD who showed post-bronchodilator forced expiratory volume in 1 second (FEV1) less than 50% of predicted value~Exclusion Criteria:~* Acute exacerbation within 4 weeks of the study entry~* Coronary heart disease~* History of adverse event on PDE-5 inhibitors

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Udenafil (Type: EXPERIMENTAL): Udenafil 50mg qd po

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete